• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by Iovance Biotherapeutics, Inc.

    < Previous 1 2 Next >
    Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2024 Financial Results Conference Call and Webcast on Thursday, November 7, 2024
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    Tickers IOVA
    Iovance Biotherapeutics to Present at Upcoming Conferences
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    Tickers IOVA
    Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    Tickers IOVA
    Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2024
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    Tickers IOVA
    Iovance Biotherapeutics to Host Second Quarter and First Half 2024 Financial Results Conference Call and Webcast on Thursday, August 8, 2024
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    Tickers IOVA
    Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    Tickers IOVA
    Iovance Biotherapeutics Submits Marketing Authorization Application to European Medicines Agency for Lifileucel in Advanced Melanoma
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    Tickers IOVA
    Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    Tickers IOVA
    Iovance Biotherapeutics to Present at Upcoming Conferences and Events
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    Tickers IOVA
    Iovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual Meeting
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    Tickers IOVA
    Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    Tickers IOVA
    Iovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate Updates
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    Tickers IOVA
    Iovance Biotherapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Thursday, May 9, 2024
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    Tickers IOVA
    Iovance Biotherapeutics to Present at Upcoming Conferences
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    Tickers IOVA
    Iovance Biotherapeutics to Present Clinical and Translational Data at 2024 ASCO Annual Meeting
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    Tickers IOVA
    Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    Tickers IOVA
    Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    Tickers IOVA
    Iovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Trial in Non-Small Cell Lung Cancer
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    Tickers IOVA
    Iovance Biotherapeutics to Present at Upcoming Conferences
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    Tickers IOVA
    Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    Tickers IOVA
    Iovance Biotherapeutics to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Wednesday, February 28, 2024
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    Tickers IOVA
    Iovance Biotherapeutics, Inc. Announces Pricing of $211 Million Underwritten Offering of Common Stock
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    Tickers IOVA
    Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    Tickers IOVA
    Iovance Biotherapeutics to Host Conference Call and Webcast on Friday, February 16, 2024
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    Tickers IOVA
    Iovance’s AMTAGVI™ (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced Melanoma
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    Tickers IOVA
    Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    Tickers IOVA
    Iovance Biotherapeutics Announces Clinical Program Update for LN-145 in Non-Small Cell Lung Cancer
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    Tickers IOVA
    Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    Tickers IOVA
    Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    Tickers IOVA
    Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2023 Financial Results and Corporate Updates
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    Tickers IOVA
    < Previous 1 2 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.